Bluejay IPO Presentation Deck

Management Bluejay is led by a team of industry veterans with years of diagnostic and product launch experience Indranil "Neil" Dey CEO and Co-founder Gordon Kinder CFO Jason Cook CTO Kevin Vance Chief Commercial Officer NanoHYBRIDS bluejay Involved in introducing Her2neu test for Herceptin (>$1.2 billion revenue) and introduction of Erbitux (>$1.15 billion revenue) Head of business development - Western U.S. for MPATH, a $300 million business unit with 65 direct reports • Ph.D. in Biochemistry (UNESCO fellow) from BRC, Hungary, MBA (Fulbright Scholar) from Cambridge University, UK More than 15 years of experience in corporate finance. Started at Ernst & Young LLP in 2005 Founded Capella Financial Services in 2008 and has served as senior finance executive for variety of companies • BA in History from Kenyon College and MBA and MS in Accounting degrees from Northeastern University Responsible for Bluejay's product development and manufacturing 15+ years of experience in the field of POC and diagnostics product development Ph.D. in Biomedical Engineering from University of Texas at Austin In charge of Bluejay's worldwide direct sales and strategic partnerships Before joining Bluejay, served as Chief Business Development Executive for Vibra Healthcare BS, Industrial Engineering & Operations Research from U. of Mass Amherst; MBA, Western New England University 4 VIBRA HEALTHCARE IMPATHE 1 Imbri EY Bulding a better Copyright (2021 Bluejay Diagnostics, Inc. All rights reserved in all slides | October 2021 16

View entire presentation